Airway pressure release ventilation (APRV). A human trial

After operative coronary revascularization, 14 consenting adults received conventional positive pressure ventilation (PPV). When they were hemodynamically stable, data were collected during PPV and then during airway pressure release ventilation (APRV). During APRV, airway pressure (Paw) was reduced...

Full description

Saved in:
Bibliographic Details
Published inChest Vol. 94; no. 4; p. 779
Main Authors Garner, W, Downs, J B, Stock, M C, Räsänen, J
Format Journal Article
LanguageEnglish
Published United States 01.10.1988
Subjects
Airway Resistance
Carbon Dioxide - blood
Cardiac Surgical Procedures
Cardiopulmonary Bypass - adverse effects
Humans
Lung Diseases - etiology
Lung Diseases - therapy
Oxygen - blood
Positive-Pressure Respiration
Postoperative Care
Respiration, Artificial - methods
Vascular Resistance
Online AccessGet more information

Cover

More Information
Summary:After operative coronary revascularization, 14 consenting adults received conventional positive pressure ventilation (PPV). When they were hemodynamically stable, data were collected during PPV and then during airway pressure release ventilation (APRV). During APRV, airway pressure (Paw) was reduced periodically at the lowest frequency which produced normal PaCO2. As anesthesia resolved, the rate of APRV breaths was decreased until patients breathed only with CPAP. During PPV and APRV, pHa, PaO2/FIO2, and hemodynamic variables were similar. All patients were weaned from APRV without complication. Optimal ventilator design for patients with acute lung injury would provide CPAP as a primary intervention and secondarily would augment alveolar ventilation. The APRV supported oxygenation and ventilation in patients with mild acute lung injury, yet with much lower peak airway pressure than produced by PPV.
ISSN:0012-3692
1931-3543
DOI:10.1378/chest.94.4.779